Do statins really cause diabetes?

A meta-analysis of major randomized controlled clinical trials

Alaa J. Rahal, PharmD, Ahmed I. ElMallah, PhD, Rita J. Poushuju, PharmD, Rana Itani, PharmD.

ABSTRACT

Objectives: To investigate and establish the relationship between the use of statin therapy and the risk of development of diabetes.

Methods: PubMed and the Cochrane Central Register of Controlled Trials was searched for randomized controlled end-point trials of statins, with more than 1000 subjects and a minimum of one-year follow-up period, published until August 2015. The odds ratio (OR) of diabetes incidence with overall statin therapy as well as with different statins in question was calculated through random effect meta-analysis model.

Results: Fourteen studies were included in the analysis with a total of 94,943 participants. Of these, 2392 subjects developed incident diabetes in the statin and 2167 in the placebo groups during a 4-year follow-up. The OR of diabetes incidence with statin therapy was significantly higher as compared with the placebo group (OR=1.11; 95% confidence interval = 1.0 to 1.2; p=0.007). There was an insignificant level of heterogeneity between the included trials (Cochran Q=19.463, p=0.109, I²=33.20). Subgroup analysis showed that only 2 statins namely, atorvastatin (OR= 1.29; p=0.042) and rosuvastatin (OR = 1.17; p=0.01) were significantly associated.

Conclusion: Statin therapy can slightly increase risk of incident diabetes in subjects with hypercholesterolemia.

Saudi Med J 2016; Vol. 37 (10): 1051-1060 doi: 10.15537/smj.2016.10.16078

Statins are established drugs for the treatment and management of cardiovascular diseases (CVD) and revolutionized the treatment of high risk patients. Statins mainly reduce serum cholesterol content by inhibiting biosynthesis of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) and isoprenoids. Other pleiotropic mechanisms of statins facilitating cardioprotective properties include...
improvement of endothelial dysfunction, increased nitric oxide bioavailability, antioxidant properties, inhibition of inflammatory responses, and stabilization of atherosclerotic plaques. Simvastatin and lovastatin are prescribed as lactone pro-drugs that are hydrolyzed enzymatically in vivo to their active hydroxy-acid form. Other statins are administered as the active hydroxyacid form.

Focused management strategies for the regulation of higher levels of low density lipoprotein cholesterol (LDL-C) in populations at the risk for coronary heart disease (CHD) have been recommended by the Adult Treatment Panel (ATP) during 1988 (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III] 1993). Critical limits for risk assessment of LDL-C have been categorized into 3 namely normal people (<3 mmol/l), high-risk people (<2.6 mmol/l) and very high-risk individuals (<1.8 mmol/l). Statins have been identified and employed as first-line therapeutics for treating high cholesterolemia since 1986. Multiple number of statins with variable therapeutic efficacies are available.

Many clinical trials have demonstrated the safety and tolerability of the statins with appreciable risk/benefit ratio and transient and mild adverse effects such as headache, rashes, and gastrointestinal symptoms. However, there is an accumulation of clinical trial data observed on the adverse effects of statins comprising an asymptomatic increase in hepatic enzymes and musculoskeletal disorders. Pooled analysis of data involving 16,495 patients from 44 clinical trials has shown that withdrawal of statin in patients due to statin related adverse events was only 3-4%, and serious treatment associated effects were reported as <1% of patients. Recent evidence suggested that the use of statins may be associated with the emergence of new cases of diabetes prompting the U.S. Food and Drug Administration (FDA) to issue a safety label change for statins. Further, in 2013 the American College of Cardiology/American Heart Association (ACC/AHA) published cholesterol treatment guidelines indicating the risk of diabetes in relation to statin therapy. Post hoc studies, intervention trials, and statistical reviews on the diabetes risk associated with statin therapy proclaimed contradictory outcomes on this critical issue between 2000 and 2011. Heterogeneity among statins in inducing diabetes among patients undergoing statin therapy was apparent through different investigations on large populations from different regions. Dose and intensity of statin therapy are other aspects being explored for their influence on onset of diabetes among patients. However, the long-term effects of statin therapy induced diabetes yet to be understood.

Numerous studies conducted during recent years provide a multitude of evidence to help understand the link between statins and diabetes with debatable findings. The present systematic review makes an effort to summarize current knowledge and improve the understanding of this phenomenon, which could help in designing a better clinical approach for statin therapy. The aim of this review is to evaluate the risk of diabetes mellitus under statin therapy, and to understand the impact of different statins on the odds of diabetes mellitus risk.

Methods. This study was conducted between March and August 2015. To retrieve all the published studies, an iterative search strategy was built up from a series of searches and thorough evaluation of the results. The strategy was built up through Population Intervention Comparison Outcomes Study Design (PICOS) methodology.

Inclusion and exclusion criteria. Randomized clinical trials examining the effects of statin therapy at an individual level with the objective of evaluating the risk of incident diabetes were included in this study. The studies, which employed placebo, or control comparison of different statins, or different doses of statins were used. In addition, studies where the sample size of patients with diabetes was more than 1000 with a mean follow-up of more than one year were included. Studies including patients on statin therapy with organ transplant, or hemodialysis were excluded for evaluation. Studies with single statin, or those in which diabetic patients on statin therapy with a sample size of less than 1000 were also excluded from the evaluation. Trials assessing change in surrogate markers of cardiovascular diseases and trials with a mean follow-up of one year, or less were also excluded. An exhaustive search strategy was developed to identify the studies for this review. The search strategies were developed for 2 major databases of Randomized Controlled Trials (RCTs) namely, the National Center for Biotechnology Information’s PubMed, and the Trials Registry of Cochrane Library.

Main outcomes of the study were analyzed by tabulation. Any significant differences in the comparison...
were recorded in the results section and interpreted logically. Risk of diabetes after statin therapy was the main result of this study.

An events rate with 95% confidence interval (CI) was chosen as most of the studies had reported events as well as sample size. The Cochran Q, a Chi square based test was used to assess the heterogeneity (between study variability) in the meta-analysis. A significance level of \( p<0.05 \) was used for statistical test of heterogeneity. While ‘Q’ statistic provided the qualitative information on the existence of heterogeneity, ‘\( I^2 \)’, that is calculated as the percentage of the total variability in a set of effect sizes due to true heterogeneity, was used to quantify the degree of heterogeneity.

High resolution forest plots were derived to estimate the pooled event rates corresponding to 95% CI and the \( p \)-value. Random effects model of meta-analysis was used for data analysis. Publication bias was investigated by using the funnel plots constructed based on the standard error by log odds ratio (OR). The report was prepared as per the standards of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.  

**Results.** Fourteen studies were found to provide the relevant data as per the criteria and were shortlisted (Figure 1). These studies provided data for 94,943 non-diabetic participants, of these, 4,599 developed incident diabetes. The mean study follow-up was 4 years (Table 1). The relative percentage reduction in blood cholesterol across the people subjected to statin therapy considered during the current review is presented in Table 2.

Heterogeneity test revealed that the included trials were homogeneous (Cochran \( Q = 19.463, \ p=0.109, \ I^2 = 33.20 \)). Rate of diabetes incidence in individual trials were found to be drastically varied (Figure 2). Of the 14 trials, 9 studies showed positive association between statin therapy and incident diabetes; however’ only 3 were significant (Pravastatin in elderly individuals at risk of vascular disease [JUPITER], Pravastatin in elderly individuals at risk of vascular disease, [PROSPER], and Stroke Prevention by Aggressive Reduction in Cholesterol Levels [SPARCL]). The overall OR of developing incident diabetes was significantly higher on statin use as compared with the control groups (OR = 1.11, \( p=0.007 \)). Since the heterogeneity was very low, variation was not attributable to chance alone.

**Figure 1** - Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines flow diagram of literature search for identification of studies.
Cumulative analysis showed that the positive effect of statins on diabetes initiation appeared after sixth \(^{22}\) and significance after the eleventh \(^{30}\) (Figure 3). Funnel plot showed that publication bias was absent as the studies were distributed symmetrically on both sides of the combined effect size and no imputed studies were plotted (Figure 4).

The OR was further analyzed based on the type of statins (Figure 5). The tests revealed that only 2 statins, atorvastatin (OR = 1.29; 95% CI = 1.0-1.6; \(p=0.042\)) and rosuvastatin (OR = 1.17 95% CI = 1.0-1.3; \(p=0.01\)) were significantly associated with diabetes.

The incidence of diabetes in the study population was highest in the placebo groups in the simvastatin trials (5.2%), followed by pravastatin (5%), atorvastatin (4.3%, \(p<0.05\)), rosuvastatin (4.2%, \(p<0.05\)), and lovastatin (2.4%). While this was lower than the treated groups in all statins, it was higher compared with the lovastatin treated subjects. The incidence was significant for atorvastatin and rosuvastatin as compared with the placebo group. Compared with lovastatin, the OR of developing incidental diabetes with pravastatin was 1.05 was times, simvastatin was 1.12 times, rosuvastatin 1.19 was times, and atorvastatin was 1.32 times.

**Discussion.** The present work is a meta-analysis of the incidence of diabetes mellitus upon chronic use

---

**Table 1** - New onset of diabetes in non-diabetic participants in 14 placebo controlled and standard care controlled statin therapy trials.

| Study    | References       | Year | Statin | Dose (mg) | Control  | Study design     | Mean follow-up (years) | Mean BMI (Kg/m²) | Mean age (years) | New DM assigned | New DM in control group |
|----------|------------------|------|--------|-----------|----------|------------------|------------------------|-------------------|------------------|-----------------|-----------------------|
| ASCOT-LLA | Sever et al \(^{17}\) | 2003 | ATO    | 10        | Placebo  | Double blind     | 3.3 \(^{3,4}\)          | 28.6              | 28.6            | 154             | 134                   |
| HPS      | Collins et al \(^{15}\) | 2003 | SIM    | 40        | Placebo  | Double blind     | 5.0                    | 27.2              | 27.2            | 335             | 293                   |
| JUPITER  | Ridker et al \(^{14}\) | 2008 | ROS    | 20        | Placebo  | Double blind     | 1.9 \(^{3}\)           | 28.4              | 28.4            | 270             | 216                   |
| WOSCOPS  | Freeman et al \(^{13}\) | 2001 | PRA    | 40        | Placebo  | Double blind     | 4.8                    | 25.9              | 25.9            | 75              | 93                    |
| LIPID    | Keech et al \(^{13}\) | 2003 | PRA    | 40        | Placebo  | Double blind     | 6.0                    | -                 | -               | 126             | 138                   |
| CORONA   | Kjekshus et al \(^{30}\) | 2007 | ROS    | 20        | Placebo  | Double blind     | 2.7 \(^{3}\)           | 27.0              | 27.0            | 100             | 88                    |
| PROSPER  | Shepard et al \(^{22}\) | 2002 | PRA    | 40        | Placebo  | Double blind     | 3.2                    | 26.5              | 26.5            | 165             | 127                   |
| MEGA     | Nakamura et al \(^{31}\) | 2006 | PRA    | 10-20    | No treatment | Open trial      | 5.3                    | 23.8              | 23.8            | 172             | 164                   |
| AFCAPS TexCAPS | Downs et al \(^{32}\) | 1998 | LOV    | 20-40    | Placebo  | Double blind     | 5.2 \(^{3}\)           | 27.0              | 27.0            | 72              | 74                    |
| 4S       | Scandinavian Simvastatin Survival Study Group \(^{17}\) | 1994 | SIM    | 20-40    | Placebo  | Double blind     | 5.4 \(^{3}\)           | 25.9              | 25.9            | 198             | 193                   |
| LLT-ALLHAT | Not Applicable | 2002 | PRA    | 40        | No treatment | Open trial      | 4.8 \(^{3}\)           | 29.0              | 29.0            | 238             | 212                   |
| GISSI HF | Tavazzi et al \(^{33}\) | 2008 | ROS    | 10        | Double blind | Open trial      | 3.9 \(^{3}\)           | 26.7              | 26.7            | 225             | 215                   |
| GISSI PREVENZIONE | Tavazzi et al \(^{33}\) | 2008 | PRA    | 20        | Double blind | Open trial      | 2.0 \(^{3}\)           | 26.3              | 26.3            | 96              | 105                   |
| SPARCL   | Waters et al \(^{26}\) | 2011 | ATO    | 80        | Placebo  | Open trial       | 4.9 \(^{3}\)           | 27.2              | 27.2            | 166             | 115                   |
| **Total** |                               |      |        |           |           |                  | \(\approx 4.0\)         | 2392             | (5.0)           | 2167            | (4.6)                 |

ASCOT-LLA - Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm, HPS - Heart Protection Study, JUPITER - Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial, WOSCOPS - West of Scotland Coronary Prevention Study, LIPID - Long-Term Intervention with Pravastatin in Ischaemic Disease Group, CORONA - Controlled Rosuvastatin Multinational Trial in Heart Failure Trial, PROSPER - Pravastatin in elderly individuals at risk of vascular disease, MEGA - Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese, AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study, 4S - Scandinavian Simvastatin Survival Study Group, LLT-ALLHAT - lipid-lowering trial component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, GISSI - Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico, HR - heart failure, GISSI PREVENZIONE - GISSI Prevention, SPARCL - Stroke Prevention by Aggressive Reduction in Cholesterol Levels, DM - diabetes mellitus, CVD - cardiovascular disease, CHD - coronary heart disease, OGTT - oral glucose tolerance test, MI - myocardial infarction, NYHA - New York Heart Association, BMI - body-mass index, PRA - pravastatin, SIM - simvastatin, ROS - rosuvastatin, ATO - atorvastatin, LOV - lovastatin, \(^{1}\)Data from total cohort (including diabetes at baseline), \(^{2}\)Weighted mean follow-up

---

1054 Saudi Med J 2016; Vol. 37 (10) www.smj.org.sa
of statins. The analysis of data showed that subjects treated with statins have a slightly higher chance of developing diabetes as compared to placebo, or standard care. Further analysis involving the comparison of different statins on diabetes incidence showed that only 2 statins, atorvastatin and rosuvastatin, showed significant association with diabetes whereas other 3 statins showed no significant incidence. Although no insights into the mechanism of these associations can be adjudged, one previous study conducted to evaluate the effects of statins on glucose transporters showed that except atorvastatin, other statins exert no detrimental effects. Therefore, the association of diabetes incidence with atorvastatin and rosuvastatin treatment was likely due to the inhibition of glucose transporters and needs further research. Statins affect insulin sensitivity through several mechanisms. A meta-analysis of 16 statin studies reporting insulin sensitivity data revealed that pravastatin can reduce the insulin secretion whereas other statins including atorvastatin, simvastatin and rosuvastatin has no such effect over insulin. Such alterations may affect insulin sensitivity and lead to diabetes.

Other studies have suggested that altered glucose uptake by decreased glucose transporter type 4 expression or translocation might be the mechanism. In vitro studies have shown that atorvastatin, but not pravastatin show impaired glucose handling. This

| Study             | References                       | Year | Statin | Dose (mg) | Control | Study design | Mean follow up (years) | Mean BMI (Kg/m²) | Mean age (years) | Relative % LDL-C reduction* |
|-------------------|----------------------------------|------|--------|-----------|---------|--------------|------------------------|-----------------|------------------|-----------------------------|
| ASCOT-LLA         | Sever et al17                     | 2003 | ATO    | 10        | Placebo | Double blind | 3.3±3,4             | 28.6†           | 28.6†            | 34.8% (12 months)†       |
| HPS               | Collins et al15                    | 2003 | SIM    | 40        | Placebo | Double blind | 5.0                   | 27.2            | 27.2             | 29.4% (average in trial) |
| JUPITER           | Ridker et al14                     | 2008 | ROS    | 20        | Placebo | Double blind | 1.9†                  | 28.4†           |                  | 50% (12 months)          |
| WOSCOPS           | Freeman et al13                    | 2001 | PRA    | 40        | Placebo | Double blind | 4.8                   | 25.9            | 25.9             | 23.7% (12 months)        |
| LIPID             | Keech et al16                      | 2003 | PRA    | 40        | Placebo | Double blind | 6.0                   | -               |                  | 25% (during 5 years)      |
| CORONA            | Kjekshus et al19                  | 2007 | ROS    | 20        | Placebo | Double blind | 2.7±3,4               | 27.0†           |                  | 45.1%† (3 months)        |
| PROSPER           | Shepherd et al12                  | 2002 | PRA    | 40        | Placebo | Double blind | 3.2                   | 26.5            | 26.5             | 30.7% (12 months)        |
| MEGA              | Nakamura et al31                  | 2006 | PRA    | 10-20    | No treatment | Open trial | 5.3                   | 23.8            | 23.8             | 17.1% (12 months)        |
| AFCAPS TexCAPS    | Downs et al39                     | 1998 | LOV    | 20-40    | Placebo | Double blind | 5.2†                  | 27.0†           |                  | 26.7% (12 months)        |
| 4S                | Scandinavian Simvastatin Survival Study Group32 | 1994 | SIM    | 20-40    | Placebo | Double blind | 5.4†                  | 25.9            | 25.9             | 36.7% (12 months)        |
| ALLHAT-LLT27      | Not Applicable                    | 2002 | PRA    | 40        | No treatment | Open trial | 4.8†                  | 29.0            | 29.0             | 18.1% (24 months)        |
| GISSI HF          | Tavazzi et al33                   | 2008 | ROS    | 10        | Placebo | Double blind | 3.9†                  | 26.7            | 26.7             | 34.9% (12 months)        |
| GISSI PREVENZIONE | Tavazzi et al33                   | 2008 | PRA    | 20        | No treatment | Open trial | 2.0†                  | 26.3            | 26.3             | 11.5% (12 months)        |
| SPARCL            | Waters et al36                    | 2011 | ATO    | 80        | Placebo | Open trial   | 4.9†                  | 27.15           |                  |                             |
| Total             |                                   |      |        |           |         |              | ≈4.0†                 |                 |                  |                             |

ASCOT-LLA - Anglo-ScandinavianCardiac Outcomes Trial-Lipid Lowering Arm, HPS - Heart Protection Study, JUPITER - Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial, WOSCOPS - West of Scotland Coronary Prevention Study, LIPID - Long-Term Intervention with Pravastatin in Ischaemic Disease Group, CORONA - Controlled Rosuvastatin Multinational Trial in Heart Failure Trial, PROSPER - Pravastatin in elderly individuals at risk of vascular disease, MEGA - Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese, AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study, 4S - Scandinavian Simvastatin Survival Study Group, ALLHAT-LLT - lipid-lowering trial component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, GISSI - Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, HR - heart failure, GISSI PREVENZIONE - GISSI Prevention, SPARCL - Stroke Prevention by Aggressive Reduction in Cholesterol Levels, DM - diabetes mellitus, CVD - cardiovascular disease, CHD - coronary heart disease, OGTT - oral glucose tolerance test, MI - myocardial infarction, NYHA - New York Heart Association, BMI - body-mass index, PRA - pravastatin, SIM - simvastatin, ROS - rosuvastatin, ATO - atorvastatin, LOV - lovastatin, *Data from total cohort (including diabetes at baseline), 1Median, †Includes only patients with normal fasting glycaemia at baseline. *Weighted mean follow-up, *Difference between the groups in the change from baseline to time point in low density lipoprotein cholesterol (LDL-C)
Figure 2 - Association between statin therapy and incident diabetes in 14 major randomized controlled trials. 4S - Scandinavian Simvastatin Survival Study Group, AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study, GISSI Prev - Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico Prevention, WOSCOPS - West of Scotland Coronary Prevention Study, PROSPER - Pravastatin in elderly individuals at risk of vascular disease, ALLHAT - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ASCOT-LLA - Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm, LIPID - Long-Term Intervention with Pravastatin in Ischaemic Disease Group, HPS - Heart Protection Study, MEGA - Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese, CORONA - Controlled Rosuvastatin Multinational Trial in Heart Failure Trial, JUPITER - Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial, HR - heart failure, SPARCL - Stroke Prevention by Aggressive Reduction in Cholesterol Levels, 95% CI - 95% confidence interval

Figure 3 - Cumulative meta-analysis of the studied clinical trial by year of publication. 4S - Scandinavian Simvastatin Survival Study Group, AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study, GISSI Prev - Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico Prevention, WOSCOPS - West of Scotland Coronary Prevention Study, PROSPER - Pravastatin in elderly individuals at risk of vascular disease, ALLHAT - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ASCOT-LLA - Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm, LIPID - Long-Term Intervention with Pravastatin in Ischaemic Disease Group, HPS - Heart Protection Study, MEGA - Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese, CORONA - Controlled Rosuvastatin Multinational Trial in Heart Failure Trial, JUPITER - Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial, HR - heart failure, SPARCL - Stroke Prevention by Aggressive Reduction in Cholesterol Levels, 95% CI - 95% confidence interval
Do statins cause diabetes ...

Figure 4 - Funnel plot of standard error by log odds ratio for the included studies on statin induced diabetes.

Figure 5 - Association between individual statins and incidental diabetes mellitus. 95% CI - 95% confidence interval

 reflects the variation in clinical effects observed with different statins. Leptin, an adipocyte-secreted hormone is another pathway through which statins may act. Leptin resistance or lowered leptin levels are believed to promote insulin resistance, leading to diabetes through a complex mechanism, including lowered insulin secretion and beta-cell depletion.38,39

Other mechanisms proposed are inhibition of glucose-induced cytosolic calcium signaling and insulin secretion through blockage of L-type calcium channels,40 impaired insulin secretion through an indirect mechanism related to chronic cholesterol depletion,41 and statin associated weight gain. However, these findings need substantial future research to associate with the observed statin effects. Another potential explanation based on the residual confounding factors suggest that improved survival, or change in lifestyle with statin therapy may promote diabetes.42 However, overall survival with control therapy and statin use has been found to be similar. This meta-analysis included all available large studies; providing good statistical power to the conducted analysis. The meta-analysis was conducted using events rate and the results were expressed as OR, as hazard ratio was not provided by all the included studies. Different methods were employed for the diagnosis of diabetes by the included trials, which are expected in such studies. Furthermore, 2 studies,15,30 The Heart Protection Study, (HPS) and the Controlled Rosuvastatin Multinational Trial in Heart Failure Trial (CORONA) were used by some physicians in reporting
for the diagnosis of diabetes, which could be unreliable as compared with diagnostic tests.

This meta-analysis studied the association between statin therapy and incidence of diabetes in 14 major randomized controlled trials. Out of 14 studies, only 9 showed a positive association between statin therapy and incident of diabetes with 3 studies (PROSPER \( p=0.022 \), JUPITER \( p=0.013 \), and SPARCL \( p=0.002 \)) showing significant association \( p<0.05 \). Further, a cumulative meta-analysis of these studied trials was carried out according to the year of publication, and it was found that positive effect of statins on diabetes mellitus initiation appeared after the sixth study, and significance after the eleventh study. All the types of statins analyzed exhibited good control over LDL-C, rosuvastatin was recorded as the highest percentage reduction over 12 months of treatment. However, its proved association with incidental diabetes, demands a reconsideration of this statin for use with cardioprotective purpose. A previous study evaluated the risk of statin drugs in incidental diabetes in identified women, elderly people, and the Asian population as the critical groups at higher chances of developing the problem. However, more studies are required for validating the higher risk of Asian people in statin therapy associated incidental diabetes.

Our results suggest that it is essential to monitor patients receiving statins for the risk factors of diabetes. Prolonged durations of use of these drugs increase the requirement of regular monitoring. In-addition, the clinical use of atorvastatin and rosuvastatin should be reconsidered, as these 2 statins showed a strong and clear association with diabetes incidence. Furthermore, it is necessary to consider development of diabetes as one of the study parameter in all the future trials of statins. This will perhaps be highly useful in extracting valuable information especially from long-term studies with great clinical implications.

Although the present meta-analysis reports an association of statins with incident diabetes such as earlier studies, the benefits of statins cannot be outweighed based on the following points: i) Statins importance in protection of the hyperlipidemic patients from severe cardiac outcomes. ii) Although the meta-analysis is significant, the rate is low. iii) Away of these factors, the patient status and demonstration could have an impact on the incidence of diabetes mellitus.

This analysis was based on studies that have been followed up for either 12 months, or more, it can also be suggested that statins may continue to be used in high risk cardiovascular patients for shorter, or medium duration treatments without a cause for concern. However, if the patients are in the low cardiovascular risk zone, it is better to reconsider the use of statins even for short term durations, especially atorvastatin and rosuvastatin. After comparing the statins OR atorvastatin was found to hold the highest OR at 1.29. After considering lovastatin, which holds the lowest OR as a reference, the association risk of diabetes mellitus for lovastatin is considered one, whereas pravastatin was found 1.05 times, simvastatin 1.12 times, rosuvastatin 1.19 times, atorvastatin 1.32 times greater for diabetes compared with lovastatin.

The study limitation of the current systematic review is that we screened only 2 databases (PubMed and Cochrane Central).

In conclusion, the current review has established the effectiveness of statins in cholesterol lowering on patients with hypercholesterolemia. The existence of positive association of statin therapy with incidental diabetes across the clinical trials has been confirmed. Comparative evaluation of different types of statins in eliciting new onset diabetes among patients has confirmed the role of atorvastatin and rosuvastatin in inducing incidental diabetes.

References

1. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003; 26 (4 Suppl 3): III32-III38.
2. Kavalipati N, Shah J, Ramakrishnan A, Vasnawala H. Pleiotropic effects of statins. Indian J Endocrinol Metab 2015; 19: 554-562.
3. Jingru Z, Xiaojian Z, Lipeng D, Ya W, Lili C. The many roles of statins in ischemic stroke. Current Neuropharmacology 2014; 12: 564-574.
4. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9-27.
5. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.
6. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B-32B.
7. Kajinami K, Mabuchi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs 2000; 9: 2653-2661.
8. Schachter M. Chemical, pharmacokinetic, and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-125.
9. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurri S, KoDT, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-2797.
Do statins cause diabetes... Rahal et al.

10. Newman CB, Palmer G, Silbershatz H, Szaerek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. *Am J Cardiol* 2003; 92: 670-676.
11. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. *BMJ* 2014; 349: 3743.
12. Stone NJ, Robinson JG, Lichtenstein AH, Bailey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014; 129 (25 Suppl 2): S1-S45.
13. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. *Circulation* 2001; 103: 357-362.
14. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008; 359: 2195-2207.
15. Collins R, Armitage J, Parish S, Sleigh P, Petro R, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003; 361: 2005-2016.
16. Keech A, Colquhoun D, Best J, Kirby A, Simes R, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. *Diabetes Care* 2003; 26: 2713-2721.
17. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Swedish Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361: 1149-1158.
18. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010; 375: 735-742.
19. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA* 2011; 305: 2556-2564.
20. Coleman CL, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. *Curr Med Res Opin* 2008; 24: 1359-1362.
21. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. *Diabetes Care* 2009; 32: 1924-1929.
22. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. *Br J Clin Pharmacol* 2013; 75: 1118-1124.
23. Danai G, Garcia Rodriguez LA, Fernandez Cantero O, Hernan MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. *Diabetes Care* 2013; 36: 1236-1240.
24. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Arch Intern Med* 2012; 172: 144-152.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009; 151: 264-269.
26. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. *J Am Coll Cardiol* 2011; 57: 1535-1545.
27. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383-1389.
28. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002; 288: 2998-3007.
29. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998; 279: 1615-1622.
30. Kjekshus J, Aperia E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007; 357: 2248-2261.
31. Nakamura H, Arakawa K, Itakura K, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet* 2006; 368: 1155-1163.
32. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360: 1623-1630.
33. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 372: 1231-1239.
34. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. *Diabetologia* 2006; 49: 1881-1892.
35. Baker WL, Talati R, White CM, Coleman CL. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. *Diabetes Res Clin Pract* 2010; 87: 98-107.
36. Brault M, Ray J, Gomez YH, Manzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. *Metabolism* 2014; 63: 735-745.
37. Takaguri A, Satoh K, Itagaki M, Togumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. *J Pharmacol Sci* 2008; 107: 80-89.
38. Cherboun M, Abitbol G, Rozenberg K, Rozenfeld H, Deutsch A, Sampson SR, et al. Maintenance of redox state and pancreatic beta-cell function: role of leptin and adiponectin. *J Cell Biochem* 2012; 113: 1966-1976.
39. Maeda T, Horiuchi N. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. *J Biochem* 2009; 145: 771-781.

40. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. *Br J Pharmacol* 1999; 126: 1205-1213.

41. Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano HY, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. *Endocrinology* 2008; 149: 5136-5145.

42. Unit ES. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005; 366: 1267-1278.

43. Goldstein MR, Mascitelli L. Do statins cause diabetes? *Curr Diab Rep* 2013; 13: 381-390.